RxDoctor Payments Data

Robert Martin, MD

Internal Medicine · Georgetown, KYNPI 1225020399

Payments from drug & device makers

$6,747in general payments, 2019–2025

Across 426 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$883
  • Lilly USA, LLC$655
  • Novo Nordisk$488
  • AbbVie$454
  • Astellas Pharma US Inc$424
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$363
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$6,65999%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,747 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$104,490
Medicare patients
222
Services billed
1,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$87,699
EliquisApixaban70$82,217
JardianceEmpagliflozin66$71,280
XareltoRivaroxaban48$52,981
XifaxanRifaximin13$40,471
ProliaDenosumab16$27,003
FarxigaDapagliflozin Propanediol17$24,847
LinzessLinaclotide35$24,551
TrulicityDulaglutide16$22,904
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$22,404
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$21,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$19,085
MyrbetriqMirabegron22$18,836
Tresiba Flextouch U-100Insulin Degludec19$16,104
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$11,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$488$87,69995 claims
Boehringer IngelheimJardiance, Stiolto Respimat$70$82,94379 claims
PfizerEliquis$245$82,21770 claims
Johnson & JohnsonXarelto$80$52,98148 claims
GSKAnoro Ellipta, Trelegy Ellipta, Arexvy$883$47,36586 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$363$40,47113 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$291$39,63942 claims
AbbVieLinzess, Savella, Synthroid$454$34,42681 claims
AmgenProlia$306$27,00316 claims
Lilly USA, LLCTrulicity$655$22,90416 claims
Astellas Pharma US IncMyrbetriq$424$18,83622 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$23$10,05911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Georgetown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →